Latest literature

Cancer research papers

Nightly index of recent papers from PubMed, bioRxiv, and medRxiv. Filters are designed for both researcher precision and patient-friendly navigation.

Learn how we rate papers in our methodology.

Starting focus

Cholangiocarcinoma

We’re indexing all cancers but highlighting cholangiocarcinoma while the evidence atlas expands.

5 papersSorted by most recent
Peer-reviewedImpact 73

Topics

Treatment, Biology / Mechanism, Side effects / Toxicity

Modality

Targeted therapy, Imaging

Study type

Lab / Preclinical

Abstract

The development of dual-targeted inhibitors represents a promising strategy to address the challenges of drug resistance and limited efficacy in cancer therapy. This study describes the design, synthesis, and evaluation of novel inhibitors targeting VEGFR2 and HDAC through a structure-based pharmacophore-merging strategy. We integrated…

Authors

Yaxin Li, Sisi Liu, Sha Hu, Ranran Zhang +9

AI-generated summary

Structure-Based Design and Free Energy Perturbation-Guided Synthesis of Novel VEGFR2 and HDAC Dual Inhibitors with Potent Antitumor Efficacy. reports: The development of dual-targeted inhibitors represents a promising strategy to address the challenges of drug resistance and limited efficacy in cancer therapy. This study describes the design, synthesis, and evaluation of novel inhibitors targeting VEGFR2 and HDAC through a structure-based pharmacophore-merging strategy. We integrated the hydroxamic acid zinc-binding group and the linker into the back pocket of VEGFR2.

This summary may be inaccurate. Verify with the primary paper.

Primary source: PubMed.

Metabolic marker profiling of circulating tumour cells in NSCLC patients treated with osimertinib: focus on MCT1 and MCT4.
Therapeutic advances in medical oncology • 2026-01-01 • DOI: 10.1177/17588359261416422
Peer-reviewedImpact 65

Topics

Treatment, Outcomes / Survival

Modality

Targeted therapy, Biomarker / Liquid biopsy, Imaging

Study type

Not listed

Abstract

Monocarboxylate transporters (MCTs) facilitate lactate transfer and support cancer cell survival and metastasis. MCT1 and MCT4 expression has been associated with poor prognosis and resistance to therapy with tyrosine kinase inhibitors. This pilot study examined the relevance of MCT1 and MCT4 expression in circulating…

Authors

Karolina Mangani, Evangelia Pantazaka, Evi Lianidou, Vassilis Georgoulias +3

AI-generated summary

Metabolic marker profiling of circulating tumour cells in NSCLC patients treated with osimertinib: focus on MCT1 and MCT4. reports: Monocarboxylate transporters (MCTs) facilitate lactate transfer and support cancer cell survival and metastasis. MCT1 and MCT4 expression has been associated with poor prognosis and resistance to therapy with tyrosine kinase inhibitors. This pilot study examined the relevance of MCT1 and MCT4 expression in circulating tumour cells (CTCs) isolated from non-small cell lung cancer (NSCLC) patients during osimertinib treatment through single-cell analysis.

This summary may be inaccurate. Verify with the primary paper.

Primary source: PubMed.

Topics

Biology / Mechanism

Modality

Targeted therapy, Imaging

Study type

Not listed

Abstract

KDM2B is a JmjC domain H3K36me2/H3K36me1 demethylase, which immortalizes cells in culture and contributes to the biology of both embryonic and adult stem cells, including cancer stem cells. Here we show that the silencing of KDM2B activates a tyrosine kinase receptor-dependent paracrine mechanism, which…

Authors

Fraile, E.-A., Soysal, B., Anastas, V., Soysal, Z. T. +4

AI-generated summary

KDM2B Silencing Elicits a Paracrine Mechanism Which Destabilizes SLUG, Promoting Differentiation of Basal-Like Breast Cancer Cells. reports: KDM2B is a JmjC domain H3K36me2/H3K36me1 demethylase, which immortalizes cells in culture and contributes to the biology of both embryonic and adult stem cells, including cancer stem cells. Here we show that the silencing of KDM2B activates a tyrosine kinase receptor-dependent paracrine mechanism, which results in the downregulation of SNAI2 (SLUG), SNAI1 (SNAIL) and SOX9, which also contribute to the biology of stem and progenitor cells. The downregulation of these molecules is posttranscriptional and in the case of SNAI2-encoded SLUG, it is due to calpain-dependent proteolytic degradation. This is a preprint and not peer reviewed.

This summary may be inaccurate. Verify with the primary paper.

Primary source: bioRxiv (not peer reviewed).

Integration of CA attention and KAN algorithm to predict EGFR mutation status in lung cancer
radiology and imaging • 2025-02-25 • DOI: 10.1101/2025.02.20.25322637
PreprintImpact 38

Topics

Treatment, Diagnosis, Biology / Mechanism

Modality

Targeted therapy, Biomarker / Liquid biopsy, Imaging

Study type

Not listed

Abstract

Epidermal Growth Factor Receptor (EGFR) mutations are critical biomarkers for targeted therapies in non-small cell lung cancer (NSCLC). However, conventional diagnostic methods rely on invasive tissue biopsies, which are costly, time-consuming, and pose significant limitations. As an alternative, non-invasive approaches using lung CT imaging…

Authors

jia, n., Xing, J., Tang, S., Liu, L. +4

AI-generated summary

Integration of CA attention and KAN algorithm to predict EGFR mutation status in lung cancer reports: Epidermal Growth Factor Receptor (EGFR) mutations are critical biomarkers for targeted therapies in non-small cell lung cancer (NSCLC). However, conventional diagnostic methods rely on invasive tissue biopsies, which are costly, time-consuming, and pose significant limitations. As an alternative, non-invasive approaches using lung CT imaging to predict EGFR mutation status have gained attention for their rapid and user-friendly nature. This is a preprint and not peer reviewed.

This summary may be inaccurate. Verify with the primary paper.

Primary source: medRxiv (not peer reviewed).

Molecular alterations in TP53, WNT, PI3K, TGF-Beta and RTK/RAS pathways in gastric cancer among ethnically heterogeneous cohorts
genetic and genomic medicine • 2025-02-24 • DOI: 10.1101/2025.02.22.25322719 • Published in 10.3390/cancers17071075
PreprintImpact 59

Topics

Biology / Mechanism, Outcomes / Survival, Prevention / Risk, Epidemiology

Modality

Targeted therapy, Imaging

Study type

Observational

Abstract

Background/ObjectivesGastric cancer (GC) remains a leading cause of cancer-related mortality worldwide, with significant racial and ethnic disparities in incidence, molecular characteristics, and patient outcomes. However, genomic studies focusing on Hispanic/Latino (H/L) populations remain scarce, limiting our understanding of ethnicity-specific molecular alterations. This study aims…

Authors

Monge, C., Waldrup, B., Carranza, F. G., Velazquez-Villarreal, E.

AI-generated summary

Molecular alterations in TP53, WNT, PI3K, TGF-Beta and RTK/RAS pathways in gastric cancer among ethnically heterogeneous cohorts reports: Background/ObjectivesGastric cancer (GC) remains a leading cause of cancer-related mortality worldwide, with significant racial and ethnic disparities in incidence, molecular characteristics, and patient outcomes. However, genomic studies focusing on Hispanic/Latino (H/L) populations remain scarce, limiting our understanding of ethnicity-specific molecular alterations. This study aims to characterize pathway-specific mutations in TP53, WNT, PI3K, TGF-Beta and RTK/RAS signaling pathways in GC and compare mutation frequencies between H/L and Non-Hispanic White (NHW) patients. This is a preprint and not peer reviewed.

This summary may be inaccurate. Verify with the primary paper.

Primary source: medRxiv (not peer reviewed).